Clinical trials: Renal Anemia
Kidney Failure, Chronic, Anemia
Cholecalciferol Supplementation for Anemia and Mineral and Bone Disorder in Hemodialysis Patients
The purpose of this study is to determine whether cholecalciferol supplementation decrease the blood concentrations of hepcidin-25 in hemodialysis patients.
- Conditions
- Kidney Failure, Chronic, Anemia, Vitamin D Deficiency, Bone Diseases, Metabolic
- Trial name
- CHAMBER (NCT02214563)
- Testing
- Cholecalciferol, Olive oil
- Where
- 7 sites in Japan
- Volunteers
- 90 people
- Sponsor
- Takayuki Hamano
Anemia in Chronic Kidney Diseases
A Phase 1 Study of SSS17 in Healthy Subjects.
This study will investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of single oral administration of 5 mg, 15 mg, 20 mg and 25 mg of SSS17 compared with placebo, and evaluate the efficacy, safety, tolerance…
- Trial name
- NCT04893187
- Testing
- SSS17
- Where
- China
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Anemia, Non-Dialysis-Dependent Chronic Kidney Disease
Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease
A multicenter, randomized, open-label, active-controlled Phase 3 study for the correction of anemia and maintenance of hemoglobin (Hb) in participants with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)
- Trial name
- NCT02648347
- Testing
- Vadadustat, Darbepoetin alfa
- Where
- 439 sites in United States, Argentina and 18 more
- Volunteers
- 1,751 people
- Sponsor
- Akebia Therapeutics
Renal Anemia
The Association Between the Distributions MCH and RBC, and Mortality in Hemodialysis Patients
Patients were classified into two groups based on the values of MCH and RBC, patients with MCH ≥30 pg but <35 pg and RBC ≤350×104/μL; and MCH <30 pg and RBC >350×104/μL.
- Trial name
- NCT04227158
- Where
- Japan
- Volunteers
- 437 people
- Sponsor
- University of Hyogo
Atypical Hemolytic Uremic Syndrome
Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment
This was a prospective, open-label study with no participant randomization. Treatment for aHUS was observational and at the discretion of the treating physician.
- Trial name
- EVIDENCE (NCT02614898)
- Testing
- Eculizumab
- Where
- 24 sites in United States, Australia and 2 more
- Volunteers
- 67 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Carcinomas, Amyloidosis
B-Receptor Signaling in Cardiomyopathy
We hope to determine the importance of different genes (including B receptors) in anthracycline-induced cardiomyopathy. This has important benefits to patients exposed to anthracyclines, as this could help determine whether…
- Conditions
- Carcinomas, Amyloidosis, Anal Cancer, Anemia
- Trial name
- NCT01135849
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Daniel Bernstein
Sickle Cell Disease Vaso-occlusive Crisis
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
This is a phase 2, randomized, multiple-dose, placebo-controlled study designed to evaluate the safety, efficacy, and pharmacokinetics (PK) of CSL889 (human hemopexin) when given intravenously (IV) to adults and adolescents with…
- Trial name
- NCT06699849
- Testing
- CSL889
- Where
- 30 sites in United States, Turkey (Türkiye) and 1 more
- Volunteers
- 70 people
- Sponsor
- CSL Behring
Chronic Kidney Disease
An Observational Study of Case Managed Versus Non-case Managed Initiation of Hemodialysis
The purpose of the study is to compare the 90 day and 12 month composite end point of death (all-cause mortality) and hospitalization in incident hemodialysis patients randomized to receive support from a dedicated case manager…
- Trial name
- PROSTARRT (NCT01613404)
- Testing
- No intervention
- Where
- 14 sites in Canada
- Volunteers
- 248 people
- Sponsor
- Janssen Inc.
Chronic Kidney Disease, Hemodialysis
Low Sirtuin-1 Levels Are Linked to Erythropoietin Resistance in Hemodialysis Patients.
This study investigates the relationship between Sirtuin-1 (SIRT1) levels and erythropoietin resistance in hemodialysis patients.
- Conditions
- Chronic Kidney Disease, Hemodialysis, Anemia in End Stage Renal Disease, Erythropoietin
- Trial name
- NCT06877286
- Testing
- Sirtuin-1 Level Measurement
- Where
- Turkey (Türkiye)
- Volunteers
- 391 people
- Sponsor
- Cuma Bulent Gul
Anemia in End-Stage Renal Disease
Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis Patients
This Phase III, randomized, two-armed, parallel, double-blind, active-controlled clinical trial is designed to compare efficacy and safety of CinnaPoietin® (Beta erythropoietin) and Eprex® (epoetin alpha) on the treatment of…
- Trial name
- NCT03408639
- Testing
- CinnaPoietin®, Eprex®, Nephrovit
- Where
- 8 sites in Iran
- Volunteers
- 156 people
- Sponsor
- Cinnagen
Healthy Volunteers
Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers
The main purpose of this study is to evaluate the effect of single oral therapeutic and supratherapeutic doses of AKB-6548 on the QT interval.
- Trial name
- NCT02062203
- Testing
- AKB-6548 (therapeutic dose), AKB-6548 (supratherapeutic dose), Moxifloxacin
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Akebia Therapeutics
Sickle Cell Disease, Renal Disease
Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia
The investigators will attempt to develop a more accurate equation to estimate eGFR in pediatric and adult sickle cell patients
- Conditions
- Sickle Cell Disease, Renal Disease, Glomerular Disease
- Trial name
- NCT04380610
- Testing
- iohexol GFR
- Where
- 4 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Anemia
A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.
This study will assess the efficacy and safety of methoxy polyethylene glycol-epoetin beta (Mircera) in the maintenance of hemoglobin levels in patients who have previously received treatment with epoetin alfa or darbepoetin…
- Trial name
- NCT00454246
- Testing
- methoxy polyethylene glycol-epoetin beta, epoetin alfa, darbepoetin alfa
- Where
- 78 sites in United States
- Volunteers
- 111 people
- Sponsor
- Hoffmann-La Roche
Chronic Kidney Disease, Anemia
A Study to Determine the Pharmacokinetic and Pharmacodynamic Profiles of PROCRIT (Epoetin Alfa) in Anemic Patients With Chronic Kidney Disease
The primary objective of this study is to describe how four different dosing regimens of PROCRIT (epoetin alfa) are utilized in patients with anemia due to non-dialysis chronic kidney disease (CKD).
- Trial name
- NCT00641589
- Testing
- epoetin alfa
- Volunteers
- 40 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CKD Anemia
A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis
The purpose of this study is to determine whether roxadustat is safe and effective in the treatment of anemia in participants with chronic kidney disease and not on dialysis.
- Trial name
- NCT01750190
- Testing
- Roxadustat
- Where
- 145 sites in United States, Argentina and 14 more
- Volunteers
- 922 people
- Sponsor
- Kyntra Bio
Anemia, Kidney Diseases
A Study to Assess Disability in Anemic Elderly Patients With Kidney Disease Receiving PROCRIT (Epoetin Alfa)
The purpose of this study is to assess disability in anemic patients over the age of 65 who have kidney disease and are receiving weekly PROCRIT® (Epoetin Alfa, a glycoprotein that stimulates red blood cell production).
- Trial name
- NCT00338468
- Testing
- epoetin alfa
- Volunteers
- 13 people
- Sponsor
- Ortho Biotech Products, L.P.
Anemia in Chronic Kidney Disease in Non-dialysis Patients
Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa
The primary objective of this study was to evaluate the efficacy of roxadustat compared to darbepoetin alfa in the treatment of anemia in nondialysis-dependent chronic kidney disease (NDD CKD) participants.
- Trial name
- Dolomites (NCT02021318)
- Testing
- Roxadustat, Darbepoetin alfa
- Where
- 125 sites in Austria, Belarus and 24 more
- Volunteers
- 616 people
- Sponsor
- Astellas Pharma Europe B.V.
Chronic Kidney Disease
EPO Deep Tank in Dialysis Subjects
Subject incidence of adverse events
- Trial name
- NCT00156949
- Testing
- Epoetin alfa DT
- Volunteers
- 580 people
- Sponsor
- Amgen
Kidney Transplantation, Anemia
Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients
The purpose of this study is to evaluate the effect of anemia correction and vitamin D supplementation in kidney transplant recipients.
- Conditions
- Kidney Transplantation, Anemia, Vitamin D Deficiency, Renal Insufficiency, Chronic
- Trial name
- CANDLE-KIT (NCT01817699)
- Testing
- High Hb target, cholecalciferol
- Where
- Japan
- Volunteers
- 161 people
- Sponsor
- CANDLE-KIT Trial Study Group
End-stage Renal Disease, Anemia
Iron Therapy in Patients With End-Stage Renal Disease
This study will compare the clinical outcome of patients with maintenance dialysis room after changing the iron treatment guidelines from original upper limit with ferritin>500ng/ml, or TSAT>20% to Ferritin> 800ng / ml, or TSAT>…
- Conditions
- End-stage Renal Disease, Anemia, Cardiovascular Risk Factor, Inflammation
- Trial name
- NCT04491916
- Testing
- irone sucrose
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital